Literature DB >> 7491218

Antiphospholipid antibodies in pediatric systemic lupus erythematosus.

D E Seaman1, A V Londino, C K Kwoh, T A Medsger, S Manzi.   

Abstract

OBJECTIVE: Antiphospholipid antibodies (aPLs) have been extensively studied in adults with systemic lupus erythematosus (SLE) and have been associated with arterial and venous thrombosis, thrombocytopenia, neurologic disorders, and recurrent fetal loss. In contrast, very little is known about the frequency and clinical significance of aPLs in pediatric SLE. This study was designed to determine the frequency of aPLs in pediatric SLE and the temporally associated clinical manifestations.
DESIGN: We studied 29 consecutive patients with onset of SLE in childhood seen in the Pediatric Rheumatology Clinic at the University of Pittsburgh, Children's Hospital, between 1985 and 1992. We defined aPL as the presence of a lupus anticoagulant (LAC), immunoglobulin G or immunoglobulin M anticardiolipin antibodies (aCLs), or a biologic false-positive serologic test for syphilis determined by a VDRL test. Clinical manifestations were temporally correlated to the presence of aPLs if they occurred within 6 months.
RESULTS: Overall, 19 (65%) of 29 children with SLE had one of the three laboratory abnormalities defining aPL. LAC was detected in 16 (62%) of 26, aCL in 18 (66%) of 27, and false-positive VDRL test results in 11 (39%) of 28. Twenty-five of the 29 patients had all three tests performed. In 10 patients, all three tests were abnormal. The presence of thrombosis in 7 patients (4 venous, 2 arterial, and 1 both) was associated with a positive aPL, specifically aCL. The presence of an aPL was significantly associated with anti-double-stranded DNA antibodies, but not with neuropsychiatric manifestations or with thrombocytopenia. The presence of an aCL was significantly associated with hemolytic anemia. A prolonged prothrombin time, in the setting of an LAC (all with a prolonged activated partial thromboplastin time), was associated with life-threatening disease in 6 of 15 patients.
CONCLUSION: Sixty-five percent of 29 consecutive pediatric patients with SLE had evidence of aPL. The presence of aPL, specifically aCL, was significantly associated with thrombotic events. The presence of a prolonged prothrombin time in the setting of an LAC may be a marker of more serious disease in pediatric SLE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491218

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

1.  Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Authors:  D M Wahezi; N T Ilowite; X X Wu; L Pelkmans; B Laat; L E Schanberg; J H Rand
Journal:  Lupus       Date:  2013-05-20       Impact factor: 2.911

2.  Antiphospholipid antibodies in children with Kawasaki disease: a preliminary study from north India.

Authors:  M George; J Ahluwalia; A Gupta; J Masih; S K Bose; S Singh
Journal:  Rheumatol Int       Date:  2013-05-15       Impact factor: 2.631

3.  Primary antiphospholipid syndrome in stroke in the young.

Authors:  A Kakar; P K Sethi
Journal:  Indian J Pediatr       Date:  1998 Sep-Oct       Impact factor: 1.967

Review 4.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

5.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

6.  Antiphospholipid antibodies in children with systemic lupus erythematosus: a prospective study in northern India.

Authors:  Jasmina Ahluwalia; Surjit Singh; Gurjeewan Garewal
Journal:  Rheumatol Int       Date:  2004-08-25       Impact factor: 2.631

7.  Autoimmune haemolytic anaemia and antiphospholipid antibodies in paediatrics: a systematic review and meta-analysis.

Authors:  Mira Merashli; Alessia Arcaro; Maria Graf; Fabrizio Gentile; Paul R J Ames
Journal:  Clin Rheumatol       Date:  2020-10-02       Impact factor: 2.980

Review 8.  The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Authors:  Chris Wincup; Yiannis Ioannou
Journal:  Front Pediatr       Date:  2018-11-27       Impact factor: 3.418

Review 9.  Peripheral nerve disease secondary to systemic conditions in children.

Authors:  Jo M Wilmshurst; Robert A Ouvrier; Monique M Ryan
Journal:  Ther Adv Neurol Disord       Date:  2019-08-12       Impact factor: 6.570

10.  The impact of antiphospholipid antibodies in children with lupus nephritis.

Authors:  Sulaiman M Al-Mayouf; Alhanouf AlSaleem; Turki Al-Hussain; Abdullah Al Sonbul; Hadeel AlMana
Journal:  Int J Pediatr Adolesc Med       Date:  2015-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.